Cumberland Pharmaceuticals Inc. — Q1 2024 Form 10-Q Summary
Business context and reporting period
Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on acquiring, developing and commercializing branded prescription products in hospital acute care, gastroenterology and oncology. The company markets six FDA-approved commercial products in the United States and maintains international partnerships and a clinical pipeline, including Phase II programs for ifetroban.
This filing reports unaudited results for the three months ended March 31, 2024, compared with the three months ended March 31, 2023. The company had 14,191,229 shares outstanding as of May 6, 2024.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net revenues | $8.5 million | $9.2 million | Down $0.7 million, or 7.9% |
| Gross profit | $6.9 million | $8.0 million | Down $1.1 million |
| Gross margin | 81.5% | 86.4% | Down 4.9 percentage points |
| Operating loss | $1.9 million | $1.5 million | Loss increased $0.3 million |
| Operating margin | (22.0%) | (16.6%) | Lower |
| Net loss attributable to common shareholders | $1.9 million | Net income of $0.2 million | Decline of $2.1 million |
| Loss per diluted share | $0.14 | Income of $0.01 | Unfavorable change |
| Cash flow from operating activities | $(2.1) million | $(1.4) million | More cash used |
| Capital expenditures and intangible additions | $0.1 million | $0.2 million | Lower |
Cost of products sold increased to $1.6 million from $1.3 million, primarily because international sales carried higher manufacturing costs as a percentage of revenue. Selling and marketing, research and development, general and administrative, and amortization expenses all decreased year over year.
Product revenue changes included Kristalose down $1.1 million to $3.2 million, Caldolor up $0.5 million to $1.5 million, Vibativ down $0.2 million to $1.6 million, Sancuso down $0.1 million to $1.8 million, and Acetadote down $0.1 million to $0.1 million. Omeclamox-Pak was discontinued, and RediTrex distribution ended in 2023.
Balance sheet, debt and liquidity
- Cash and cash equivalents were $18.5 million at March 31, 2024, compared with $18.3 million at December 31, 2023.
- Working capital was $9.8 million, compared with $7.7 million at year-end 2023; the current ratio was 1.4 versus 1.3.
- Borrowings under the revolving credit facility increased to $16.1 million from $12.8 million. The applicable interest rate was 8.125% at March 31, 2024.
- Reported revolver availability was $3.9 million at March 31, 2024, compared with $7.2 million at December 31, 2023.
- The revolving facility has aggregate potential funding of up to $25 million, an initial revolving amount of up to $20 million, a maturity date of October 1, 2026, and is secured by substantially all company assets.
- On May 6, 2024, the company amended the credit agreement to provide an alternative covenant structure based on a borrowing base certificate and eligible cash and accounts receivable.
- Total inventories were $17.2 million, including $12.9 million classified as non-current. Management reported no cumulative obsolescence or discontinuance losses at March 31, 2024.
Material changes versus the prior comparable period
- Revenue declined 7.9%, primarily due to lower Kristalose shipments, lower Vibativ and Sancuso sales, and reduced Acetadote revenue. Caldolor growth and higher other revenue partially offset the declines.
- The prior-year period included $1.8 million of other income related to a gain on an FDA fee receivable; no comparable income was recorded in Q1 2024. This was the principal reason the company moved from prior-year net income to a current-year net loss.
- Operating loss widened despite lower operating expenses because of reduced revenue and substantially higher product cost as a percentage of sales.
- Operating cash use increased to $2.1 million, driven primarily by the net loss, a $1.1 million increase in accounts receivable, and a $0.6 million decrease in accounts payable and other current liabilities.
- Financing activities provided $2.4 million, including $3.3 million of net revolver borrowings, partially offset by contingent consideration payments and $0.2 million of share repurchases.
- The company repurchased 125,870 shares for approximately $0.2 million during the quarter. Approximately $2.8 million remained available under the repurchase authorization at March 31, 2024.
Guidance, outlook, commentary, risks and unusual items
Management did not provide specific numerical revenue or earnings guidance. Management stated that existing working capital, internally generated resources and the revolving credit facility are expected to be adequate to finance internal growth, business development initiatives and capital expenditures for the foreseeable future, although the company continues to depend on product sales, financing availability and market conditions.
- Sancuso: A new FDA-approved manufacturing facility has been completed, and Cumberland expects to begin shipping Cumberland-branded product during 2024.
- Vaprisol: The company has no branded product inventory available and is awaiting FDA-related resolution for a new manufacturer. Interim compounded product generated only limited revenue in the quarter.
- Caldolor: Management expects potential separate Medicare reimbursement under the NOPAIN Act for qualifying products furnished beginning January 1, 2025, but CMS had not yet established the final eligibility or reimbursement amount.
- Ifetroban: Three Phase II programs are underway in systemic sclerosis, Duchenne muscular dystrophy cardiomyopathy and idiopathic pulmonary fibrosis. Development outcomes, regulatory approval and commercialization remain uncertain.
- Product and supply risks: The business relies on third-party manufacturers and packagers. Manufacturing, FDA inspection, supply interruptions, product returns, rebates, chargebacks and inventory obsolescence could affect results.
- Acquisition obligations: Contingent consideration liabilities totaled approximately $5.7 million for Vibativ and Sancuso at March 31, 2024, with related royalty and milestone payments continuing.
- Financing risk: Borrowings bear variable interest rates and are collateralized by substantially all assets. The company may require additional debt or equity capital to support acquisitions, development and operations.
- Other unusual items: Omeclamox-Pak was discontinued after the company could not identify an alternative packager, and RediTrex rights were returned to Nordic in 2023 in exchange for a potential long-term royalty.
- The company reported no material adverse expectation from existing litigation and no off-balance-sheet arrangements. Management concluded that disclosure controls and procedures were effective as of March 31, 2024.
Important facts for investors to verify
- Whether Kristalose shipment timing normalizes and whether the company can stabilize overall product revenue.
- Progress toward FDA approval and commercial availability of branded Vaprisol supplies.
- Timing, eligibility and reimbursement levels under the NOPAIN Act for Caldolor.
- Actual Sancuso shipment volumes and the financial effect of the new manufacturing arrangement.
- Revolver covenant compliance, borrowing-base availability, variable interest expense and liquidity if operating cash flow remains negative.
- Cash requirements and results of the ifetroban Phase II programs, including clinical, regulatory and funding risks.
- Potential inventory impairment or obsolescence, particularly the $12.9 million of non-current inventory.
- Future contingent consideration, royalties and milestone payments associated with Vibativ and Sancuso.
- Whether share repurchases and the newly established ATM capacity remain appropriate given the company’s operating cash use and increased debt.